SCHEMBL25518835

SCHEMBL25518835

CC(C)C[C@H](NC(=O)CNC(=O)C(C)C)B1OC2C[C@H]3C[C@H](C3(C)C)[C@@]2(C)O1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 19/20 0.65
PSMB1 P20618 8/20 0.65
PSMB11 A5LHX3 7/20 0.65
PSMA7 O14818 7/20 0.65
PSMA1 P25786 7/20 0.65
PSMA2 P25787 7/20 0.65
PSMA3 P25788 7/20 0.65
PSMA4 P25789 7/20 0.65
PSMB8 P28062 7/20 0.65
PSMB9 P28065 7/20 0.65
PSMA5 P28066 7/20 0.65
PSMB4 P28070 7/20 0.65
PSMB6 P28072 7/20 0.65
PSMB10 P40306 7/20 0.65
PSMB3 P49720 7/20 0.65
PSMB2 P49721 7/20 0.65
PSMA6 P60900 7/20 0.65
PSMA8 Q8TAA3 7/20 0.65
PSMB7 Q99436 7/20 0.65
PSMD11 O00231 4/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015576 0.91 PSMB5 (0.63) PSMB5PSMB1PSMB11PSMA7PSMA1
SCHEMBL20972365 0.91 PSMB5 (0.63) PSMB5PSMB1PSMB11PSMA7PSMA1
SCHEMBL25518828 0.90 PSMB5 (0.62) PSMB5PSMB1PSMB11PSMA7PSMA1
SCHEMBL22113435 0.89 PSMB5 (0.68) PSMB5PSMB1PSMB11PSMA7PSMA1
SCHEMBL14043421 0.88 PSMB5 (0.64) PSMB5PSMB1PSMB11PSMA7PSMA1
SCHEMBL13451115 0.88 PSMB5 (0.64) PSMB5PSMB1PSMB11PSMA7PSMA1
SCHEMBL24214122 0.88 PSMB5 (0.59) PSMB5PSMB1PSMB11PSMA7PSMA1
SCHEMBL20779065 0.87 PSMB5 (0.67) PSMB5PSMB1PSMB11PSMA7PSMA1
SCHEMBL2331686 0.87 PSMB5 (0.67) PSMB5PSMB1PSMB11PSMA7PSMA1
SCHEMBL13416356 0.87 PSMB5 (0.67) PSMB5PSMB1PSMB11PSMA7PSMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF HDAC6, PSMG3, PSMB2 PSMB5 9/4885PSMB1 6/4885PSMB11 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.